Standard treatment of exudative ARMD is repeat intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibody, ranibizumab, aflibercept, or pegabtanib, which are legally accepted but expensive. The gene discussed is VEGFA; the disease is age-related macular degeneration.